Literature DB >> 23662157

Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges.

Maud Lemoine1, Shevanthi Nayagam, Mark Thursz.   

Abstract

Chronic viral hepatitis is a major public health issue worldwide and mostly affects resource-limited countries. These regions combine a considerable set of barriers to containing the epidemic, including shortage of healthcare workers, poor medical infrastructures, insufficient screening and poor access to care and treatment. At a time when morbidity and mortality of chronic liver disease has been widely improved in wealthy countries by new innovative strategies and potent antiviral drugs, it is now urgent to face the challenges of better management of chronic hepatitis in resource-poor countries from the perspectives of global health and social justice.

Entities:  

Keywords:  DAA; HBV; HCC; HCV; HIV/AIDS; global health; resource-limited countries; social justice; treatment

Year:  2013        PMID: 23662157      PMCID: PMC3646239          DOI: 10.2217/fvl.13.11

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  53 in total

1.  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2012-03-20       Impact factor: 25.083

Review 2.  Hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

Review 3.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

4.  Hepatitis B virus infection amongst pregnant women in North-eastern Nigeria- a call for action.

Authors:  A B Olokoba; F K Salawu; A Danburam; L B Olokoba; J K Midala; L H Badung; Awo Olatinwo
Journal:  Niger J Clin Pract       Date:  2011 Jan-Mar       Impact factor: 0.968

Review 5.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

6.  HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.

Authors:  H N Kim; J Scott; A Cent; L Cook; R A Morrow; B Richardson; K Tapia; K R Jerome; G Lule; G John-Stewart; M H Chung
Journal:  J Viral Hepat       Date:  2011-05-13       Impact factor: 3.728

7.  Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV.

Authors:  Huey-Ling Chen; Lung-Huang Lin; Fu-Chang Hu; Jian-Te Lee; Wen-Terng Lin; Yao-Jung Yang; Fu-Chen Huang; Shu-Fen Wu; Solomon Chih-Cheng Chen; Wan-Hsin Wen; Chia-Hsiang Chu; Yen-Hsuan Ni; Hong-Yuan Hsu; Pei-Lin Tsai; Cheng-Lun Chiang; Ming-Kwang Shyu; Ping-Ing Lee; Feng-Yee Chang; Mei-Hwei Chang
Journal:  Gastroenterology       Date:  2011-12-23       Impact factor: 22.682

Review 8.  Clinical implications of HIV and hepatitis B co-infection in Asia and Africa.

Authors:  Christopher J Hoffmann; Chloe L Thio
Journal:  Lancet Infect Dis       Date:  2007-06       Impact factor: 25.071

9.  Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa.

Authors:  Balint Stewart; Modou L Jobarteh; Ramu Sarge-Njie; Abraham Alabi; Thushan de Silva; Kevin Peterson; Ingrid Peterson; Hilton Whittle; Sarah Rowland-Jones; Assan Jaye; Matthew Cotten; Maimuna Mendy
Journal:  BMC Res Notes       Date:  2011-12-23

10.  Injection drug use is a risk factor for HCV infection in urban Egypt.

Authors:  Adela Paez Jimenez; Mostafa K Mohamed; Noha Sharaf Eldin; Hasnaa Abou Seif; Said El Aidi; Yehia Sultan; Nasr Elsaid; Claire Rekacewicz; Mostafa El-Hoseiny; May El-Daly; Mohamed Abdel-Hamid; Arnaud Fontanet
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

View more
  38 in total

Review 1.  Current and Future Burden of Chronic Nonmalignant Liver Disease.

Authors:  Prowpanga Udompap; Donghee Kim; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2015-08-17       Impact factor: 11.382

Review 2.  Hepatitis B virus epidemiology.

Authors:  Jennifer H MacLachlan; Benjamin C Cowie
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

3.  HIV, Hepatitis B Virus, and Hepatitis C Virus Prevalence Among High-Risk Populations in South India.

Authors:  Thongadi Ramesh Dinesha; Jayaseelan Boobalan; Sathasivam Sivamalar; Sunil S Solomon; Selvamuthu Poongulali; Ambrose Pradeep; Kailapuri G Murugavel; Pachamuthu Balakrishnan; Davey M Smith; Shanmugam Saravanan
Journal:  AIDS Res Hum Retroviruses       Date:  2018-01-17       Impact factor: 2.205

Review 4.  Screening and diagnosis of HBV in low-income and middle-income countries.

Authors:  Jean-Pierre Allain; Ohene Opare-Sem
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-14       Impact factor: 46.802

Review 5.  Hepatitis B virus: where do we stand and what is the next step for eradication?

Authors:  Haruki Komatsu
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

6.  Disparate distribution of hepatitis B virus genotypes in four sub-Saharan African countries.

Authors:  Joseph C Forbi; Yousr Ben-Ayed; Guo-liang Xia; Gilberto Vaughan; Jan Drobeniuc; William M Switzer; Yury E Khudyakov
Journal:  J Clin Virol       Date:  2013-07-17       Impact factor: 3.168

7.  Prevalence and vaccination coverage of Hepatitis B among healthcare workers in Cameroon: A national seroprevalence survey.

Authors:  Chanceline Bilounga Ndongo; Lucrèce Eteki; Mark Siedner; Rose Mbaye; Jennifer Chen; Rodrigue Ntone; Olivier Donfack; Brian Bongwong; Rachel Essaka Evoue; Florence Zeh; Richard Njouom; Georges Nguefack-Tsague; Georges Alain Etoundi Mballa; Magloire Biwole Sida; Yap Boum
Journal:  J Viral Hepat       Date:  2018-08-28       Impact factor: 3.728

8.  Exploring the anti-HIV-1 reverse transcriptase, anti-inflammatory, anti-cancer activities and cytotoxicity of two fermented commercial herbal concoctions sold in Limpopo Province of South Africa.

Authors:  Matimba I Ntlhamu; Ashwell R Ndhlala; Peter Masoko
Journal:  BMC Complement Med Ther       Date:  2021-05-26

9.  HBsAg seroprevalence among Senegalese militaries.

Authors:  Abdoul A Ndiaye; Ibrahima Socé Fall; Gora Lo; Sidy Mouhamed Seck; Alioune Badara Tall; Boubacar Gueye; Amady Barro Mbodj; Anta Tal-Dia
Journal:  Mil Med Res       Date:  2015-02-24

10.  Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.

Authors:  Mehlika Toy; David W Hutton; Samuel K So
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.